No Data
The clinical trial application for the anti-TL1A monoclonal antibody SSGJ-627 independently developed by Sunshine Guojian Pharmaceutical has been accepted.
Shanghai, January 9, 2025 /PR Newswire/ -- Recently, Sunshine Guojian Pharmaceutical (688336.SH) independently developed anti-TL1A monoclonal antibody (development code: SSGJ-627) clinical trial application has been accepted by the National Pharmaceutical Administration, becoming the first domestically produced anti-TL1A monoclonal antibody to apply for and receive approval for clinical trials. TL1A (TNF ligand-related molecule 1A) is a member of the tumor necrosis factor superfamily, primarily expressed by endothelial cells. It binds to DR3 (death receptor 3) to provide stimulation signals for downstream signaling pathways, regulating the proliferation, activation, apoptosis, and cellular indicators of effector cells.
Sunshine Guojian Pharmaceutical (688336.SH): The SSGJ-627 injection has received the acceptance notification for the drug clinical trial application.
On January 9, Gelonghui announced that Sunshine Guojian Pharmaceutical (688336.SH) has received the "Acceptance Notification" issued by the National Medical Products Administration, and the clinical trial application for SSGJ-627 injection (project code "SSGJ-627") has been accepted. SSGJ-627 injection is an innovative research and development product by Sunshine Guojian Pharmaceutical, possessing independent intellectual property rights for recombinant anti-TL1A humanized monoclonal antibody. TL1A (TNF ligand-related molecule 1A) is a member of the tumor necrosis factor superfamily, primarily expressed by endothelial cells. It binds to DR3 (death receptor 3) to provide downstream signaling pathways.
Is Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336) A Risky Investment?
The listing application for sunshine guojian pharmaceutical's recombinant anti-IL-17A humanized monoclonal antibody injection 608 has been accepted by the National Medical Products Administration.
Shanghai, November 19, 2024 /PR Newswire/ -- Sunshine Guojian Pharmaceutical (stock code: 688336.SH) announced that the application for listing of its recombinant anti-IL-17A humanized monoclonal antibody injection (608), recently submitted to the National Medical Products Administration, was accepted on November 18, for the treatment of adult moderate to severe plaque psoriasis. 608 is an innovative monoclonal antibody against IL-17A independently developed by Sunshine Guojian Pharmaceutical. In August of this year, the key registration Phase III clinical trial of 608 for the treatment of adult moderate to severe plaque psoriasis completed unblinding and final statistical analysis, with all primary therapeutic effects.
Sunshine Guojian Pharmaceutical's Q3 Profit Jumps 50%; Shares Fall 3%
Sansei Guojian: Third Quarter Report 2024
What Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd's (SHSE:688336) 29% Share Price Gain Is Not Telling You
No Data
